People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment
Authors' conclusion
Lower baseline PF was associated with a higher prevalence of ORCs. Patients taking tirzepatide experienced substantial weight loss, regardless of their baseline PF. Tirzepatide may improve PF through both weight loss-dependent and -independent mechanisms, especially in those with lower baseline PF.
Study context
- Population
- Participants of SURMOUNT-1 (2539), SURMOUNT-3 (579) and SURMOUNT-4 (670) trials of tirzepatide in obesity3 SURMOUNT trials
- Comparison
- Baseline physical function (PF) quartiles among tirzepatide-treated participants
Methodological detailsgrouped by baseline quartiles of SF-36v2 PF scores, ANCOVA
- Grouped by baseline quartiles of SF-36v2 PF scores
- ANCOVA
Primary result
As reported in the abstract
Q1
12.5
Q4
−0.8
Further findings
Obesity-related complications (ORCs) by baseline PF (SURMOUNT-1)
- Lower baseline PF had more ORCs
Weight, waist circumference and BMI reductions with tirzepatide across quartiles (SURMOUNT-1)
- Weight reduction (kg), range across quartiles
- −20.1% to −22.8%
- Waist circumference reduction, range across quartiles
- −17.2 to −20.2 cm
- BMI reduction, range across quartiles
- −7.2 to −9.0 kg/m²
- Reductions similar across quartiles
Correlation between weight reduction and PF improvement
- Weak to mild correlation; strength decreased from Q1 to Q4
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →